After-Hours Stock Movers:

Spruce Biosciences, Inc. (NASDAQ: SPRB) 24.2% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $15.00.

Eloxx Pharma (NASDAQ: ELOX) 9.2% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $4.00.

Rivian Automotive (NASDAQ: RIVN) 6.4% LOWER; reported Q3 EPS of ($12.21), versus ($2.88) reported last year. Announces 71K net preorders for R1 in U.S. and Canada. Sees planned ~200K annual capacity at Normal, IL, and estimated 400K annual capacity at Georgia facility.

Steelcase (NYSE: SCS) 6.2% LOWER; reported Q3 EPS of $0.08, $0.01 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $738.2 million versus the consensus estimate of $767.62 million. Steelcase sees Q4 2022 EPS of $0.00, versus the consensus of $0.12. Steelcase sees Q4 2022 revenue of $740-765 million, versus the consensus of $770.77 million.

FedEx (NYSE: FDX) 5.8% HIGHER; reported Q2 EPS of $4.83, $0.56 better than the analyst estimate of $4.27. Revenue for the quarter came in at $23.5 billion versus the consensus estimate of $22.44 billion. FedEx (NYSE: FDX) sees FY 2022 EPS of $20.50 to $21.50, versus the consensus of $19.64.

Shift4 Payments, Inc. (NYSE: FOUR) 3.8% HIGHER; authorized the commencement of a stock repurchase program. The stock repurchase program authorizes the Company to repurchase up to $100 million of the Companys Class A common stock, par value $0.0001 (Common Stock) and will expire on December 31, 2022, subject to market conditions, contractual restrictions and other factors.

General Motors Company (NYSE: GM) 3.6% LOWER; Dan Ammann, the CEO of the self-driving division Cruise, is leaving the company, with Kyle Vogt, the President and CTO of Cruise to serve as an interim CEO.

United States Steel Corporation (NYSE: X) 3.6% LOWER; provided fourth quarter 2021 guidance. Fourth quarter 2021 adjusted EBITDA is expected to be approximately $1.65 billion.

Biomea Fusion Inc. (NASDAQ: BMEA) 2.8% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $22.00.